Indian pharmaceutical company Cipla Ltd has announced a change in its leadership, with current Chief Operating Officer (COO) Achin Gupta set to take over as the company’s next Chief Executive Officer (CEO) and Managing Director. Gupta will succeed Umang Vohra, who has decided not to seek re-appointment after completing his current term on March 31, 2026. The transition is part of a planned succession process developed by the company’s board, and Gupta’s appointment is subject to shareholder approval.

Gupta, who joined Cipla in 2021 and became COO in February 2025, will assume his new role on April 1, 2026, for a five-year term. As COO, he currently oversees the company’s commercial markets, active pharmaceutical ingredient, manufacturing, and supply chain operations. Gupta has a strong educational background, holding an MTech in Biochemical Engineering and Biotechnology from IIT Delhi and an MBA from IIM Ahmedabad.

Outgoing CEO Umang Vohra has been with Cipla since 2015, serving as Global Chief Financial & Strategy Officer before taking over as MD & CEO in 2016. Cipla’s chairman, Dr. Y K Hamied, thanked Vohra for his dedication and contributions to the company, wishing him success in his future endeavors. Dr. Hamied expressed confidence in Gupta’s ability to lead Cipla to its next phase of growth and progress.

Gupta has expressed his honor at being entrusted with the responsibility of leading Cipla, stating that he is committed to driving the company’s purpose of “Caring for Life” and combining business with a humanitarian approach. With Gupta at the helm, Cipla is expected to continue its focus on delivering high-quality, affordable medicines to patients worldwide. The company’s planned transition is seen as a positive move, ensuring continuity and stability in its leadership, and positioning Cipla for future success in the competitive pharmaceutical industry.

Cipla Limited, a leading pharmaceutical company, has announced the appointment of Achin Gupta as its new Managing Director and Global Chief Executive Officer (MD & GCEO), effective April 1, 2026. Gupta will succeed Umang Vohra, who has led the company since 2016. This transition is part of Cipla’s robust succession strategy, ensuring continuity and stability for the company’s future growth.

Achin Gupta has been with Cipla since 2021, serving as CEO of the One India Business and later as Global Chief Operating Officer (GCOO) since February 2025. During his tenure, he has driven exceptional growth and operational excellence, achieving market-leading profitability and expanding the company’s presence in chronic therapies and underserved geographies. Gupta has also strengthened Cipla’s position as a preferred innovation-led collaborator through strategic global partnerships.

As the new MD & GCEO, Gupta has expressed his commitment to driving sustainable growth, deepening the company’s impact across markets, and continuing to innovate with purpose. He is inspired by Cipla’s legacy of purpose-driven innovation and patient-centric care, and he has witnessed the passion and resilience of the company’s teams.

The leadership transition marks an important milestone in Cipla’s nearly nine-decade journey of advancing access to affordable, quality healthcare. The company is committed to innovation and patient care, and under Gupta’s leadership, it will build on its legacy and strengthen global partnerships. Cipla will continue to shape the future of healthcare through innovation and purpose, with a focus on driving growth, expanding its presence, and improving the lives of patients worldwide.

The transition is seen as a seamless one, with Gupta’s experience and leadership style well-suited to take the company forward. The company’s robust succession strategy has ensured that the transition is smooth, and the future of Cipla looks bright under Gupta’s leadership. With his vision and commitment, Cipla is poised to continue its journey of providing affordable and quality healthcare to patients around the world.

Cipla Health, a leading consumer healthcare company in India, has launched a new brand called Unfold, which marks its entry into the sexual wellness category. Unfold aims to promote openness, trust, and choice in intimate wellbeing, and its visual identity was developed in collaboration with dCell, the design arm of MullenLowe Lintas Group. The goal was to create a modern and distinctive look that would set a fresh tone for the category and stand out among global condom labels.

According to Shivam Puri, Managing Director and CEO of Cipla Health, the company is committed to providing wellness products that enhance overall health and wellbeing. With Unfold, the company has entered the sexual wellness category with products guided by strong consumer insights, where trust is a paramount consumer need. The packaging design plays a crucial role in establishing brand credentials, and dCell has translated these insights into a modern packaging design that feels fresh and reframes intimacy while staying stigma-free.

The design of Unfold’s logo and packaging is inspired by the idea of “unfolding” layers of passion and intimacy. The bold, vibrant colors and dynamic design system evoke excitement and desire, while a metallic holographic finish adds a layered, premium appeal. Bhumika Shah, Executive Design Director at dCell, notes that Unfold is more than just a product – it’s a step towards normalizing conversations around intimacy in India. The brand’s stylish, modern, and aspirational identity reflects a growing demand for sexual wellness products that are discreet, aesthetically appealing, and uncompromising on quality.

The response to Unfold has been encouraging, with both consumers and trade partners showing positive feedback. The brand is on its journey to deliver real impact and promote a more open and stigma-free conversation around intimacy in India. With Unfold, Cipla Health aims to provide a fresh perspective on the sexual wellness category and establish itself as a leader in the market. The brand’s modern and distinctive design is expected to appeal to a new generation of consumers who are looking for products that are both effective and aesthetically pleasing.

Cipla Health, a leading healthcare company, has launched a new brand called Unfold, marking its entry into the sexual wellness segment. The brand’s design and visual identity were developed by dCell, a design agency, to redefine how intimacy is represented in India’s healthcare market. Unfold’s packaging features a modern and minimal aesthetic, positioning the brand alongside global names in the sexual wellness space while resonating with Indian consumers.

According to Shivam Puri, Managing Director and CEO of Cipla Health, the launch of Unfold is a significant step towards providing wellness products that focus on enhancing overall health and wellbeing. The company conducted extensive consumer research to understand the needs and preferences of Indian consumers, and the findings guided the development of Unfold’s product offerings. Puri emphasized that trust is a paramount consumer need in the sexual wellness category, and packaging plays a crucial role in establishing brand credentials.

The packaging design of Unfold was created to be fresh, modern, and stigma-free. The design features bold, vibrant colors and a dynamic system that evokes excitement and desire. A metallic holographic finish adds a premium appeal to the packaging. Bhumika Shah, Executive Design Director at dCell, explained that Unfold is more than just a product – it’s a step towards normalizing conversations around intimacy in India. The brand’s design reflects a growing demand for sexual wellness products that are discreet, aesthetically appealing, and uncompromising on quality.

With the launch of Unfold, Cipla Health expands its wellness portfolio and addresses evolving consumer attitudes towards intimacy and self-care. The brand’s design-forward approach bridges functionality and emotion, offering a unique and refreshing perspective on the sexual wellness category. The response from consumers and trade partners has been encouraging, and Unfold is poised to make a significant impact in the market. Overall, Unfold represents a significant step forward in promoting healthy and open conversations about intimacy and sexual wellness in India.

India’s weight-loss market has welcomed a new player with the launch of ‘Yurpeak’ by Cipla, a popular pharmaceutical company. Yurpeak is the brand name given to the medication Mounjaro, which has been approved by the US FDA for the treatment of type 2 diabetes. However, its effectiveness in weight loss has also been widely recognized. With the introduction of Yurpeak, Cipla aims to tap into the growing demand for weight-loss solutions in India.

Mounjaro, the original medication, is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood sugar levels and promotes weight loss. Clinical trials have shown that Mounjaro can lead to significant weight loss, with some patients losing up to 15-20% of their body weight. This has generated significant interest in the medication as a potential treatment option for obesity.

Cipla’s entry into the weight-loss market with Yurpeak is strategic, given the increasing prevalence of obesity and related health issues in India. The country is home to a large population struggling with weight-related problems, and the market for weight-loss solutions is expected to grow significantly in the coming years. By launching Yurpeak, Cipla is poised to capitalize on this trend and establish itself as a major player in the Indian weight-loss market.

The launch of Yurpeak is also expected to increase awareness about the importance of weight management and the availability of effective treatment options. Cipla plans to promote Yurpeak through a targeted marketing campaign, highlighting its benefits and effectiveness in weight loss. The company will also engage with healthcare professionals to educate them about the medication and its potential to address the growing obesity epidemic in India.

While the launch of Yurpeak is a significant development in India’s weight-loss market, it is essential to note that the medication should only be used under medical supervision. As with any prescription medication, there may be potential side effects and risks associated with Yurpeak, and patients should consult their healthcare provider before starting treatment.

In conclusion, the launch of Yurpeak by Cipla marks a new era in India’s weight-loss market. With its proven effectiveness in weight loss and Cipla’s strong presence in the Indian pharmaceutical market, Yurpeak is expected to make a significant impact on the country’s obesity landscape. As the demand for weight-loss solutions continues to grow, Cipla is well-positioned to capitalize on this trend and establish itself as a leader in the Indian weight-loss market.

Cipla, a leading Indian pharmaceutical company, has been honored with a customized stamp released by India Post to commemorate its 90th anniversary. The ₹5 stamp features the image of Dr. YK Hamied, a doyen of Cipla, with the company’s recent Mumbai office as the backdrop. The release of the stamp was attended by Dr. Hamied, his brother MK Hamied, and other Cipla employees, and was also live-streamed to the company’s global offices and sites.

The stamp was released by Suchita Joshi, Postmaster General of Navi Mumbai, in September, although the company had actually turned 90 in August. This milestone is a significant achievement for Cipla, which has established itself as one of the leading generic pharmaceutical companies in India and across the world. The company has a strong presence in Africa, the USA, Europe, and other selected markets.

Dr. Hamied had earlier stated that Cipla would continue to provide accessible and quality products to India and the world. He also outlined the company’s future focus areas, including respiratory, cardiac, cancer, obesity, and mental health segments, as well as anti-microbials. This is not the first time a pharmaceutical company has been honored with a customized stamp in India. Earlier this year, GlaxoSmithKline (GSK) had a stamp released to mark its 100 years in the country.

The release of the customized stamp is a testament to Cipla’s contributions to the pharmaceutical industry and its commitment to providing quality products to patients worldwide. As the company looks to the future, it is likely to continue playing a significant role in shaping the global healthcare landscape. With its strong presence in various markets and its focus on critical therapeutic areas, Cipla is well-positioned to address the evolving healthcare needs of patients around the world. The company’s 90th anniversary is a significant milestone, and the customized stamp is a fitting tribute to its achievements.

Yusuf Hamied, the Chairman of Cipla, is a leader who has transformed the global pharmaceutical landscape by advocating for affordable medications and lifesaving therapies. Born on July 25, 1936, in Vilnius, Lithuania, Hamied moved to India with his family and later studied Natural Sciences at Christ’s College, Cambridge, and earned his PhD in Organic Chemistry from the University of Cambridge. His experiences in science and the international community shaped his mindset, and he disagreed with the traditional pharma leaders who prioritized profit over people.

Before Hamied took over, Cipla was a respected Indian company with limited international influence. However, under his leadership, Cipla expanded its reach to over 80 countries, providing medications not just in India but also in Africa, Latin America, Europe, and Asia. Hamied’s vision was to introduce affordable global healthcare, and he achieved this by providing antiretroviral medications for HIV/AIDS at a price of $1 per day, shocking the powerful pharmaceutical companies in the West.

Hamied’s leadership was marked by innovation, and he invested in cutting-edge biotechnology and biosimilars. He created world-class manufacturing in India with quality equal to international standards. Cipla’s global impact was significant, and the company became a leader in providing affordable treatments for HIV/AIDS, COVID-19, respiratory care, and cancer. Today, Cipla is active in over 80 countries, with over 25,000 employees and a revenue of ₹22,000 crore+ (approx. 2.7 billion USD).

Despite facing challenges such as patent issues and regulatory regulations, Hamied remained guided by his moral compass, which emphasized compassion, innovation, and access. He believed that healthcare is a right, not a privilege, and that values have a longer-term impact than quarterly profits. Hamied’s journey is a testament to the fact that humanity and commercial viability can go hand in hand, and he has demonstrated that success is not just defined by numerics but by the lives changed and the positive impact created.

Hamied’s legacy is a challenge to future entrepreneurs and corporate leaders to redefine the societal role of business. His bravery in challenging global corporations and his assertion that healthcare is a fundamental human right make him one of India’s most transformative leaders today. As the Chairman of Cipla, Hamied continues to promote affordable access to essential medicines, and his work has saved millions of lives worldwide. His story is a reminder that business can be a force for good, and that leaders like Hamied can make a significant impact on the world.

The Indian Media Awards (IMA) 2025 Grand Jury consists of esteemed industry professionals, including Shivam Puri, Managing Director & CEO of Cipla Health Ltd. As reported by Exchange4Media, the IMA 2025 aims to recognize and celebrate excellence in the media industry.

Shivam Puri, with his extensive experience in the healthcare sector, brings a unique perspective to the Grand Jury. As the CEO of Cipla Health Ltd, he has been instrumental in shaping the company’s strategy and driving growth. His expertise in marketing, sales, and product development will be valuable assets to the jury.

The IMA 2025 Grand Jury will be responsible for evaluating entries across various categories, including media planning, media buying, and media research. The jury will assess the entries based on criteria such as innovation, creativity, and effectiveness. With Shivam Puri on board, the jury will have a comprehensive understanding of the healthcare sector and its media requirements.

The Indian Media Awards have been a benchmark for excellence in the media industry for several years. The awards recognize and reward outstanding work in media, and the Grand Jury plays a crucial role in selecting the winners. The jury’s decisions are based on a rigorous evaluation process, ensuring that the winners are truly deserving of the recognition.

The inclusion of Shivam Puri in the IMA 2025 Grand Jury is a testament to his reputation as a thought leader in the healthcare industry. His participation will not only bring a new perspective to the jury but also ensure that the awards are given to the most deserving candidates. As the media industry continues to evolve, the IMA 2025 will provide a platform for professionals to showcase their work and be recognized for their achievements.

The Exchange4Media report highlights the importance of the IMA 2025 and the role of the Grand Jury in selecting the winners. With Shivam Puri as part of the jury, the awards are expected to be even more competitive and prestigious. The IMA 2025 will be a significant event in the media industry, and the participation of industry leaders like Shivam Puri will make it a memorable occasion. Overall, the IMA 2025 Grand Jury, including Shivam Puri, will play a vital role in recognizing and celebrating excellence in the media industry.

Bora Biologics has partnered with InvaGen Pharmaceuticals, a subsidiary of Cipla Group, to manufacture NYPOZI(TM) at its San Diego facility. This partnership marks a significant milestone in the production of NYPOZI(TM), a crucial medication for patients in need. Bora Biologics’ state-of-the-art facility in San Diego will be utilized to manufacture the drug, leveraging the company’s expertise in biologics manufacturing.

InvaGen Pharmaceuticals, as a Cipla Group company, brings extensive experience in pharmaceutical development and commercialization to the table. The collaboration between Bora Biologics and InvaGen Pharmaceuticals aims to ensure a stable and efficient supply chain for NYPOZI(TM), meeting the growing demand for this essential medication.

Under the terms of the partnership, Bora Biologics will be responsible for the manufacturing of NYPOZI(TM) at its San Diego facility, while InvaGen Pharmaceuticals will handle the regulatory and commercial aspects of the product. This strategic partnership will enable both companies to pool their resources and expertise, ultimately benefiting patients who rely on NYPOZI(TM) for their treatment.

The San Diego facility, where NYPOZI(TM) will be manufactured, is equipped with cutting-edge technology and staffed by experienced professionals. Bora Biologics’ commitment to quality and adherence to regulatory standards will ensure that NYPOZI(TM) is produced with the highest level of excellence.

This collaboration is a testament to the growing trend of partnerships in the pharmaceutical industry, where companies are coming together to leverage their strengths and expertise to bring essential medications to market. The partnership between Bora Biologics and InvaGen Pharmaceuticals is expected to have a positive impact on patients, healthcare providers, and the pharmaceutical industry as a whole.

With the manufacturing of NYPOZI(TM) at Bora Biologics’ San Diego facility underway, patients can expect a steady supply of this vital medication. The partnership between Bora Biologics and InvaGen Pharmaceuticals demonstrates the companies’ dedication to improving patient outcomes and advancing the field of biologics manufacturing. As the demand for NYPOZI(TM) continues to grow, this collaboration will play a critical role in ensuring that patients have access to the medication they need.

In a significant development, Cipla, a leading pharmaceutical company, is undergoing a leadership shift. Umang Vohra, the current Managing Director and Global Chief Executive Officer (CEO), has decided to exit the company. Vohra’s departure marks the end of an era at Cipla, where he has been instrumental in shaping the company’s strategy and driving its growth over the past few years.

As Vohra prepares to leave, Achin Gupta, the current Chief Financial Officer (CFO), is likely to take over as the new Global CEO of Cipla. Gupta has been with the company for several years and has played a key role in driving its financial strategy and growth. His appointment as CEO is expected to be a smooth transition, given his familiarity with the company’s operations and his experience in the pharmaceutical industry.

Vohra’s decision to exit Cipla is seen as a surprise move, given his successful tenure at the company. During his leadership, Cipla has expanded its presence in global markets, launched several new products, and strengthened its research and development capabilities. Vohra has also been credited with driving the company’s digital transformation and building a strong leadership team.

The leadership shift at Cipla comes at a time when the company is facing intense competition in the pharmaceutical industry. The company has been investing heavily in research and development, and has been exploring new opportunities in areas such as biotechnology and digital health. Gupta’s appointment as CEO is expected to ensure continuity and stability at the company, and to drive its future growth and strategy.

Gupta’s background and experience make him an ideal candidate to lead Cipla. He has a strong track record of driving financial growth and has been instrumental in shaping the company’s strategy. He is also known for his leadership skills and his ability to build strong teams. With Gupta at the helm, Cipla is expected to continue its growth trajectory and to remain a major player in the pharmaceutical industry.

Overall, the leadership shift at Cipla marks a new chapter for the company. While Vohra’s exit is a loss, Gupta’s appointment as CEO is expected to ensure continuity and stability. With a strong leadership team and a clear strategy, Cipla is well-positioned to drive growth and innovation in the pharmaceutical industry. The company’s future looks bright, and investors and stakeholders will be watching with interest as Gupta takes over as Global CEO.

Indian pharmaceutical company Cipla is reportedly preparing for a significant management change. Umang Vohra, the company’s managing director and global CEO, is expected to step down by the end of the current fiscal year. Vohra, 54, has been in the role for nearly a decade. Achin Gupta, currently Cipla’s global chief operating officer, is likely to take over as his replacement. According to an industry executive, Gupta has been groomed for the role over the past few years and is expected to assume the position by March 2026.

Cipla is a major player in the pharmaceutical industry, manufacturing active pharmaceutical ingredients for other companies, as well as a range of pharmaceutical and personal care products. The company is the world’s largest producer of antiretroviral drugs and has a significant presence in over 80 countries worldwide. In India, Cipla operates 34 manufacturing units across eight locations.

One of Cipla’s notable achievements was the launch of Remdesivir, an antiviral medication, under the brand name CIPREMI in July 2020. The medication was approved for “restricted emergency use” in critically ill COVID-19 patients, following a voluntary licensing agreement with Gilead Sciences and approval from the Drug Controller General of India (DCGI).

The management change is expected to take place over the next year, with Gupta likely to take over the role of managing director and global CEO. The transition is seen as a planned move, with Gupta having been prepared for the position over the past few years. The change is expected to have a significant impact on the company’s operations and strategy, although the exact details of the transition are not yet clear.

Cipla’s products include a range of medications, such as escitalopram oxalate, lamivudine, and fluticasone propionate. The company’s global presence and reputation as a major pharmaceutical manufacturer make it a significant player in the industry. As the company prepares for the management change, it will be interesting to see how the transition affects its operations and strategy in the coming months.

Teva Pharmaceutical Industries Ltd. has reached a settlement agreement to dismiss its patent-infringement lawsuit against Cipla Ltd., an Indian generic-drug maker, over proposed copies of its Qvar RediHaler asthma treatment. The agreement was approved by Judge Stanley R. Chesler in a consent order of dismissal issued in the US District Court for the District of New Jersey. The terms of the agreement were not disclosed, and neither Teva nor Cipla has commented on the matter.

Teva had filed the lawsuit in February 2024, seeking to block Cipla’s generic version of Qvar RediHaler, which is an inhalation aerosol used to treat asthma. The lawsuit alleged that Cipla’s proposed generic would infringe on Teva’s patents related to the medication. By settling the case, Teva has ended its efforts to prevent Cipla from launching a generic version of Qvar RediHaler, at least for the time being.

The agreement does not necessarily mean that Cipla will be able to launch its generic version of Qvar RediHaler immediately. The consent order of dismissal leaves the door open for either side to renew allegations in the future, suggesting that the dispute may not be fully resolved. Teva may still try to block Cipla’s generic version of Qvar RediHaler if it believes that Cipla’s product infringes on its patents.

The settlement is significant because it could impact the availability of affordable asthma treatments in the US. Qvar RediHaler is a prescription medication that is used to control and prevent symptoms of asthma. A generic version of the medication could provide a more affordable option for patients who rely on Qvar RediHaler to manage their asthma.

Overall, the settlement between Teva and Cipla highlights the complex and often contentious nature of patent disputes in the pharmaceutical industry. The agreement may have implications for patients, healthcare providers, and the pharmaceutical industry as a whole, and its impact will likely be closely watched in the coming months and years.

Cipla, a leading pharmaceutical company, is confident in its ability to withstand the potential impact of tariff threats on its business. In a recent interview, Cipla’s CEO, Umang Vohra, emphasized that the company has “one of the most well-diversified models” in the industry, which would help mitigate the effects of tariff changes.

Vohra explained that Cipla’s diversified portfolio, which includes a mix of domestic and international businesses, would cushion the company from the potential fallout of tariffs. The company has a significant presence in various markets, including the US, Europe, and emerging markets, which would help spread the risk. Additionally, Cipla has a diversified product portfolio, with a range of therapies and products, including respiratory, cardiac, and anti-infective medicines.

The CEO also highlighted Cipla’s strong manufacturing capabilities, which would enable the company to adapt to changes in tariffs. Cipla has a robust manufacturing network, with facilities in India, the US, and other countries, which would allow the company to shift production to other locations if needed. This flexibility would help minimize the impact of tariffs on the company’s operations.

Vohra noted that while tariffs are a concern, they are not a new challenge for the company. Cipla has been navigating tariff changes and other trade-related issues for many years and has developed strategies to manage these risks. The company has a strong track record of adapting to changing market conditions and has a robust risk management framework in place.

Cipla’s diversified model and strong manufacturing capabilities have enabled the company to deliver consistent growth and performance, despite the challenges posed by tariffs and other factors. The company has reported strong revenue growth in recent quarters, driven by its domestic and international businesses.

In conclusion, Cipla’s CEO, Umang Vohra, is confident that the company’s diversified model and strong manufacturing capabilities would help mitigate the impact of tariff threats. With a diversified portfolio, robust manufacturing network, and strong risk management framework, Cipla is well-positioned to navigate the challenges posed by tariffs and other trade-related issues. The company’s consistent growth and performance demonstrate its ability to adapt to changing market conditions, and it is likely to continue to deliver strong results in the future. Overall, Cipla’s diversified model and strong manufacturing capabilities make it a resilient and attractive investment opportunity.

The US Food and Drug Administration (USFDA) has issued a single observation for Cipla’s Bommasandra facility, which is a pharmaceutical manufacturing plant located in Karnataka, India. The observation was made after the USFDA conducted an inspection of the facility from February 14 to February 18, 2022.

The USFDA issues observations under its Form 483, which is a list of conditions or practices that are required to be corrected in order to comply with the agency’s regulations. In this case, the single observation issued to Cipla’s Bommasandra facility indicates that the company has been found to be in compliance with most of the USFDA’s regulations, with only one minor issue that needs to be addressed.

The USFDA’s observation is related to the company’s quality control procedures, which are designed to ensure the purity, potency, and safety of the pharmaceutical products manufactured at the facility. While the observation does not specify the exact nature of the issue, it is likely related to a minor deviation from the company’s standard operating procedures (SOPs) or a failure to properly document certain quality control activities.

Cipla, which is one of India’s largest pharmaceutical companies, has stated that it is taking steps to address the observation and ensure that the facility is in full compliance with the USFDA’s regulations. The company has a strong track record of compliance with regulatory requirements and has previously received approvals from the USFDA for several of its products.

The issuance of a single observation is not uncommon, and it is seen as a minor setback for the company. In fact, many pharmaceutical companies receive observations from the USFDA during the course of an inspection, and it is up to the company to address the issue and ensure that it is in compliance with the agency’s regulations.

Overall, the USFDA’s observation of Cipla’s Bommasandra facility is a normal part of the regulatory process, and it does not necessarily indicate any major issues with the company’s quality control procedures or its ability to manufacture safe and effective pharmaceutical products. The company will likely address the observation and continue to operate the facility in accordance with the USFDA’s regulations.

Amit Patel has been promoted to Head of Consumer Marketing Excellence at Cipla India, a leading pharmaceutical company. In his new role, Patel will be responsible for driving consumer marketing across various therapeutic areas, with a focus on building patient-centric and insight-led narratives. He expressed his excitement and gratitude for the opportunity, reflecting on his journey so far and the impact of his previous campaigns, which aimed to shift perceptions, build awareness, and create connections between patients and therapies.

Patel has over 15 years of experience in marketing and brand strategy, having worked across geographies and industries. Prior to joining Cipla, he held key positions at several companies, including Dabur International Ltd, VLCC International LLC, and Karan Communications, where he began his career as a Creative Coordinator. His professional strengths include critical thinking, public relations, digital marketing, brand development, and strategic planning.

As Head of Consumer Marketing Excellence, Patel will leverage his expertise to drive impactful and purpose-driven ideas at scale. He is committed to strengthening Cipla’s commitment to building patient-centric narratives and contributing to the company’s legacy of caring for life. Patel’s promotion is a testament to his hard work and dedication, and he is looking forward to the new challenges and opportunities that his expanded role will bring.

Patel’s experience and skills will be valuable assets to Cipla as the company continues to navigate the evolving healthcare landscape. His ability to think critically and develop effective marketing strategies will help drive growth and innovation in the company’s consumer marketing efforts. With his new role, Patel is poised to make a significant impact at Cipla and contribute to the company’s mission of improving the lives of patients and communities. Overall, Patel’s promotion is a significant development for Cipla, and his expertise and leadership will be instrumental in shaping the company’s consumer marketing efforts in the years to come.

Cipla EMEU and Cipla Limited have been recognized at the Healthcare Asia Pharma Awards 2025 for their innovative initiatives. Cipla EMEU received the ESG Program of the Year – India award for its Ahead & Apart campaign, which promotes sustainable practices in the healthcare ecosystem. The campaign has three core strategies: communication, certification, and sustainable reminders, and has already engaged over 27,000 healthcare professionals (HCPs) across seven countries. The initiative aims to encourage the adoption of Environmental, Social, and Governance (ESG) practices and has earned several achievements, including the prestigious Zero Waste to Landfill Certification.

On the other hand, Cipla Limited received the Most Differentiated Service of the Year – India award for its Breathefree Digital Educator initiative. This platform provides personalized and tech-enabled guidance to patients on how to use their inhalers correctly, addressing the critical barrier to effective treatment in respiratory healthcare. Patients can access the platform by scanning a QR code on their inhaler packaging, which directs them to a live video consultation with a healthcare professional. The platform tracks patient engagement and provides valuable insights to refine educational strategies.

Both initiatives demonstrate the companies’ commitment to innovation and excellence in the pharmaceutical industry. The Ahead & Apart campaign strengthens Cipla’s reputation as a global sustainability leader, while the Breathefree Digital Educator initiative delivers real-world impact by helping patients breathe better and live healthier lives. The Healthcare Asia Pharma Awards recognizes companies in Asia that have redefined pharmaceutical excellence and gives recognition to game-changers and visionaries who possess unwavering commitment to innovation and excellence.

The awards are presented by Healthcare Asia Magazine, and the full list of winners can be viewed on their website. The magazine also invites companies to join the 2026 awards programme and be recognized for their innovative initiatives that have enhanced their business and made remarkable contributions to the pharmaceutical industry. The recognition of Cipla EMEU and Cipla Limited’s initiatives serves as a testament to their dedication to a healthier and greener future, and their commitment to making a positive impact in the lives of patients and healthcare professionals alike.

Pharmaceutical company Cipla has announced the date for its earnings release for the fourth quarter and full year ended March 31, 2025. The company’s Board of Directors is scheduled to meet on Tuesday, May 13, 2025, to consider and approve the standalone and consolidated audited financial results. Based on its past trend, Cipla is expected to announce the results post-market hours on May 13.

The company also indicated that it may recommend a final dividend for FY25 during the upcoming board meeting. Cipla has a history of rewarding shareholders with healthy dividend payouts, with a dividend of ₹13 declared in 2024, up from ₹8.50 in 2023 and ₹5 in 2022.

Additionally, Cipla announced that its trading window for dealing in securities will remain closed from April 1 to May 15, 2025, in compliance with insider trading regulations and in view of the upcoming financial results.

Looking back, Cipla’s Q3 results for FY25 showed a 49% jump in consolidated net profit to Rs 1,571 crore, compared to Rs 1,056 crore in the same quarter a year ago. Revenue from operations grew 7% YoY to Rs 7,073 crore. Sequentially, the net profit rose 21% from Rs 1,303 crore in Q2 FY25, while revenue showed a marginal increase from Rs 7,051 crore.

Cipla, a leading global pharmaceutical company, has signed an exclusive licensing agreement to expand its ophthalmology portfolio and global offerings. The agreement involves the acquisition of Formosa Pharmaceuticals’ US FDA-approved clobetasol propionate 0.05% ophthalmic suspension (APP13007).

Under the agreement, Cipla will have exclusive rights to market and distribute APP13007 in India and South Africa. The product is a corticosteroid designed for the treatment of various ocular inflammatory conditions, including inflammatory posterior uveitis, chorioretinitis, and anterior uveitis.

With this new addition, Cipla’s ophthalmology portfolio is poised to benefit from the growing demand for treatment options in this area. Clobetasol propionate 0.05% ophthalmic suspension has already received US FDA approval, making it a valuable asset for Cipla’s global offerings.

The expansion of Cipla’s ophthalmology portfolio is strategic, as the company continues to diversify its product range and strengthen its presence in key markets. The agreement reflects Cipla’s commitment to investing in products that cater to unmet medical needs and address specific therapeutic areas.

The inclusion of APP13007 in Cipla’s portfolio is expected to enhance the company’s competitiveness in the ophthalmology space, particularly in India and South Africa. The deal also underscores Cipla’s ability to identify and acquire complementary products that align with its business strategy.

The agreement with Formosa Pharmaceuticals marks a significant milestone in Cipla’s ongoing efforts to expand its global footprint and expand its product offerings. This development is likely to be seen as a further endorsement of Cipla’s position as a leading healthcare company, committed to delivering high-quality treatments to patients worldwide.

Overall, the exclusive licensing agreement with Formosa Pharmaceuticals is a significant step towards Cipla’s continued growth and expansion, as it bolsters its ophthalmology portfolio and increases its global presence.